News
Amgen's fundamentals stay strong with rising EPS, dividend yield, and new drug momentum, despite technical pullbacks. See why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback